Trial Parameters
Condition Autoimmune Diseases
Sponsor University Hospital, Brest
Study Type OBSERVATIONAL
Phase N/A
Enrollment 670
Sex ALL
Min Age 18 Years
Max Age 99 Years
Start Date 2021-05-11
Completion 2027-05
Brief Summary
The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM. This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of one of the autoimmune diseases Exclusion Criteria: * Treatment with rituximab in the previous 12 months